Osteoporosis Drugs Market

Key Highlights of the report

How are the major segments performing in the Osteoporosis Drugs Market?

• In 2022, Selective Estrogen Inhibitors Modulator (SERM) dominated the drug class segment as it can mimic and block estrogen’s effect on different tissues by interacting with estrogen receptors in different cells.
• In 2022, the injectable segment was anticipated to hold a prominent share of the global osteoporosis drugs market. As injectable drugs can be taken longer than oral ones and more people find it easy to have injectable medicine as it does not upset the stomach, this segment will grow.

What is the Market Size of Osteoporosis Drugs regarding value?

The global osteoporosis drugs market is anticipated to grow at a substantial CAGR of 5.5% in the upcoming years. The global osteoporosis drugs industry was estimated to be worth USD 15.1 billion in 2022 and was expected to be worth USD 21.9 billion by 2028.

Which region dominated the Osteoporosis Drugs Market?

In 2022, North America dominated the osteoporosis drugs market; with a growing population, surging cases of obesity and increasing lifestyle-related diseases, the region dominates the osteoporosis drugs market. A survey found out 34 million Americans have inadequate bone density and are at high risk of fracture. Out of these, 30% of people are suffering from the problem of osteoporosis. The region is dominating with the increase in government regulations to prevent and protect the disease from spreading and finding the cure properly.

How is US Market Performing in the Osteoporosis Drugs Market?

In 2022, around 1.5 million people faced the problem of osteoporosis and fracture in the U.S. Every year, the use of osteoporosis drugs is high in the country as to the healthcare agencies’ sanctions and guidelines for the patients suffering from the disease. With the change in lifestyle, the increase in healthcare expenditure, and regular research and development work, the growth in osteoporosis care units in the country is growing the fastest in the market worldwide.

How is the Economy Impacting Global Osteoporosis Drugs market growth?

With the leading economic indicators and the government’s spending a significant share on healthcare infrastructure, the osteoporosis drugs market will grow rapidly. An increasing number of hospitals and clinics, and pharmacies. The drug manufacturers are funded. Various brands of medicines are available for people to choose from according to their spending. The market is growing quickly worldwide. The number of healthcare workers is increasing in numbers, and research and development are always funded for constant drug development.

What is the competitive environment of the Osteoporosis Drugs market?

The global osteoporosis market is highly competitive; therefore, the major players have adopted several strategies to gain maximum market share. There have been collaborations, mergers, acquisitions and new product launches by the players in the market. The companies are constantly working on their research sections to develop and update the drug qualities with time.

Executive Summary

What are the key trends in the Osteoporosis Drugs Market?

• In 2022, advances in the molecular comprehension of bone metabolism and bioengineering will help find new ways to treat osteoporosis in the future, with the help of paradigms like antibody therapeutics, gene therapies and stem cell therapies.
• In 2021, because of the developments in pharmaceutical research in the field of osteoporosis, a personalized therapeutic setting will help the selection of the most suitable and effective treatment for the disease with the lowest amount of detrimental effects.

How are Osteoporosis Drugs used to treat the disease?

With the help of lifestyle changes, osteoporosis drugs work the best. There are various steps by which these drugs are given to patients. Usually, bisphosphonates are given for osteoporosis treatment, including alendronate risedronate and others. Another common medication for osteoporosis is denosumab, which might be used for people who cannot take bisphosphonate due to allergies or reduced kidney function. Denosumab is delivered with the help of shallow injections, just under the skin and every six months. Stopping this drug have serious consequences like spinal cord fracture; therefore, the doctors advice taking medicine consistently. There are both intravenous as well as oral medications available for the patients. These medications reduce the rate at which the bones break down by speeding up the bone-building processes.

Which are the key investments by the Osteoporosis Drugs market players?

Market players are focusing on research and development to improve the market for the end-use industries. For instance, in April 2020, Amgen Inc. got U.S. FDA approval for its drug EVENITY to treat osteoporosis in postmenopausal women at high risk for fractures. In August 2019, Radius Health, Inc. started the Phase 3 wearABLe Study in its research section for treating Abaloparatide-Patch in Postmenopausal Osteoporosis Patients at very high risk for fracture.

Some major digital diagnostics players are Amgen Inc., F. Hoffmann-La Roche AG, Radius Health, Inc., Merck & Co. Inc., Novartis International AG (Sandoz), Pfizer Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.

What are the Major Driving Factors for the Osteoporosis Drugs Market?

With the increase in the per capita income of the people, their expenditure is in different areas. People have started focusing on their health and paying attention to improving it. Therefore the increase in healthcare expenditure will be the major driver of the market. With the surge in the prevalence of different types of diseases and rising government initiatives for people’s health and the improvement in healthcare infrastructure and increasing the affordability of treatment and diagnosis for various medical conditions, the market is set to grow rapidly. As the governments in different countries are investing a significant amount of GDP in healthcare, in developed and developing countries like the U.S. in North America and India in Asia and the guidelines by WHO to maintain the people’s health, this trend will drive the market.

What are the Major Risks for the Osteoporosis Drugs Market?

Adverse effects of the drugs are restraining the growth of the market. The rise in healthcare awareness and new technologies that can replace drugs are the factors that can restrain the market. The factors such as the patent expiry of the drugs, as well as the adverse effects of the drugs, are the factors that are hindering the growth. The side effects of the anti-inflammatory drugs are their slow efficacy, and other side effects of the osteoporosis drugs, such as vomiting, leg cramps, diarrhea and others, are also restraining the market.

Which is the key platform in the Osteoporosis Drugs market?

During the forecast period, the Selective Estrogen Inhibitors Modulator (SERM) dominated the drug class segment as it can mimic and block estrogen’s effect on different tissues by interacting with estrogen receptors in different cells. It increases bone density by 2 to 3 percent in the lower hips and spine. It also reduces spinal fractures by upto 50 percent and 22 percent in other regions.

How is the Osteoporosis Drugs market performing in regions?

The greatest revenue share in the Osteoporosis Drugs market was attributed to North America. Easy availability of osteoporosis drugs and surge in healthcare advancement, the technical advancement in the detection of the disease and further the cure of it. The research and development in the orthopedic department. With the growing number of cases of the disease due to the busy lifestyle of people, the market for osteoporosis drugs in the regions will be growing significantly. On the other hand, the Asia Pacific market is expected to grow significantly in the forecasted years. The consistent R&D investment in the healthcare sector in this region and the presence of prominent players in developing economies like India and China, and their efforts to commercialize branded medicines at relatively low prices are driving the market in the region.

What is the regulatory landscape for the Osteoporosis Drugs market?

As stated by FDA, the Guidelines for the Clinical Evaluation of Drugs Used in the treatment of osteoporosis will help find a more accurate cure for the disease. FDA and EMA both have established guidance documents on conducting osteoporosis clinical trials. These trials’ objective is to develop a drug treatment for osteoporosis. As outlined in 1994 FDA guidelines for osteoporosis trials, the approval included; normal bone quality in a subset of clinical trial participants, normal bone quality in preclinical studies of two animal species, and a clinical and significant increase in bone mineral density.

What are the major players planning for the future of the Osteoporosis Drugs market?

In April 2020, Amgen Inc. got U.S. FDA approval for its drug EVENITY (romosozumab-aqqg) for treating osteoporosis in postmenopausal women at high risk for fracture. In August 2019, Radius Health, Inc. started the Phase 3 wearABLe Study in its research section for treating Abaloparatide-Patch in Postmenopausal Osteoporosis Patients at very high risk for fracture.

Segmentation of Global Osteoporosis Drugs Market-

Global Digital Diagnostics Market – By Drug Class

• Bisphosphonates
• Selective Estrogen Inhibitors Modulator (SERM)
• Parathyroid Hormone Therapy
• Calcitonin
• Rank Ligand Inhibitors
• Others

Global Digital Diagnostics Market – By Route of Administration

• Oral
• Injectable
• Other

Global Digital Diagnostics Market – By Region

• North America
  • U.S
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • South-east Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Approach Adopted
1.3.4.1. Top-Down Approach
1.3.4.2. Bottom-Up Approach
1.3.5. Assumptions
1.4. Market Introduction
1.5. Market Research Scope

2. Executive Summary
2.1. Market Snapshot: Global Osteoporosis Drugs Market
2.2. Global Osteoporosis Drugs Market, By Drug Class
2.3. Global Osteoporosis Drugs Market, By Route of Administration
2.4. Global Osteoporosis Drugs Market, By Region

3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Osteoporosis Drugs Market Value, 2022-2030, (US$ Bn)
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.2. Market Restraints
3.2.3. Market Opportunities
3.2.4. Major Industry Challenges
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. Drug Class
3.5.2. Route of Administration
3.5.3. Geography

4. Premium Insights
4.1. STAR (Situation, Task, Action, Results) Analysis
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Medical of Buyers/Consumers
4.2.3. Bargaining Medical of Suppliers
4.2.4. Threat of Substitute Drug Class
4.2.5. Intensity of Competitive Rivalry
4.3. Key Market Trends
4.3.1. Demand Side Trends
4.3.2. Supply Side Trends
4.4. Value Chain Analysis
4.5. Technology Analysis
4.6. Analysis and Recommendations
4.7. Marketing Strategy Analysis
4.7.1. Direct Marketing
4.7.2. Indirect Marketing
4.7.3. Marketing Channel Development Trend

5. Market Positioning of Key Players, 2022
5.1. Company market share of key players, 2022
5.2. Competitive Benchmarking
5.3. Market Positioning of Key Vendors
5.4. Geographical Presence Analysis
5.5. Major Strategies Adopted by Key Players
5.5.1. Key Strategies Analysis
5.5.2. Mergers and Acquisitions
5.5.3. Partnerships
5.5.4. Drug Class Launch
5.5.5. Geographical Expansion
5.5.6. Others

6. Economic Impact Analysis
6.1. Recession Impact
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Latin America
6.1.5. Middle East and Africa
6.2. Ukraine-Russia War Impact
6.2.1. North America
6.2.2. Europe
6.2.3. Asia Pacific
6.2.4. Latin America
6.2.5. Middle East and Africa
6.3. COVID-19 Impact Analysis
6.3.1. North America
6.3.2. Europe
6.3.3. Asia Pacific
6.3.4. Latin America
6.3.5. Middle East and Africa

7. Global Osteoporosis Drugs Market
7.1. Global Osteoporosis Drugs Market, by Drug Class, 2022-2030(US$ Bn)
7.1.1. Overview
7.1.2. Global Osteoporosis Drugs Market, By Drug Class, 2022 vs 2030 (in%)
7.1.3. Global Osteoporosis Drugs Market, By Bisphosphonates, 2022-2030 (US$ Bn)
7.1.4. Global Osteoporosis Drugs Market, By Selective Estrogen Inhibitors Modulator (SERM), 2022-2030 (US$ Bn)
7.1.5. Global Osteoporosis Drugs Market, By Parathyroid Hormone Therapy, 2022-2030 (US$ Bn)
7.1.6. Global Osteoporosis Drugs Market, By Calcitonin, 2022-2030 (US$ Bn)
7.1.7. Global Osteoporosis Drugs Market, By Rank Ligand Inhibitors, 2022-2030 (US$ Bn)
7.1.8. Global Osteoporosis Drugs Market, By Others, 2022-2030 (US$ Bn)
7.2. Global Osteoporosis Drugs Market, by Route of Administration, 2022-2030(US$ Bn)
7.2.1. Overview
7.2.2. Global Osteoporosis Drugs Market, By Route of Administration, 2022 vs 2030 (in%)
7.2.3. Global Osteoporosis Drugs Market, By Oral, 2022-2030 (US$ Bn)
7.2.4. Global Osteoporosis Drugs Market, By Injectable, 2022-2030 (US$ Bn)
7.2.5. Global Osteoporosis Drugs Market, By Others, 2022-2030 (US$ Bn)

8. North America Osteoporosis Drugs Market Analysis
8.1. North America Osteoporosis Drugs Market, by Drug Class, 2022-2030(US$ Bn)
8.1.1. Overview
8.1.2. SRC Analysis
8.2. North America Osteoporosis Drugs Market, by Route of Administration, 2022-2030(US$ Bn)
8.2.1. Overview
8.2.2. SRC Analysis
8.3. North America Osteoporosis Drugs Market, by Country, 2022-2030(US$ Bn)
8.3.1. U.S.
8.3.1.1. U.S. Osteoporosis Drugs Market Estimates and Forecast, 2022-2030 (US$ Bn)
8.3.1.2. U.S. Osteoporosis Drugs, By Drug Class, 2022-2030 (US$ Bn)
8.3.1.3. U.S. Osteoporosis Drugs, By Route of Administration, 2022-2030 (US$ Bn)
8.3.2. Canada
8.3.2.1. Canada Osteoporosis Drugs Market Estimates and Forecast, 2022-2030 (US$ Bn)
8.3.2.2. Canada Osteoporosis Drugs, By Drug Class, 2022-2030 (US$ Bn)

9. Europe Osteoporosis Drugs Market Analysis
9.1. Europe Osteoporosis Drugs Market, by Drug Class, 2022-2030(US$ Bn)
9.1.1. Overview
9.1.2. SRC Analysis
9.2. Europe Osteoporosis Drugs Market, by Route of Administration, 2022-2030(US$ Bn)
9.2.1. Overview
9.2.2. SRC Analysis
9.3. Europe Osteoporosis Drugs Market, by Country, 2022-2030 (US$ Bn)
9.3.1. Germany
9.3.1.1. Germany Osteoporosis Drugs Market Estimates and Forecast, 2022-2030 (US$ Bn)
9.3.1.2. Germany Osteoporosis Drugs, By Drug Class, 2022-2030 (US$ Bn)
9.3.1.3. Germany Osteoporosis Drugs, By Route of Administration, 2022-2030 (US$ Bn)
9.3.2. France
9.3.2.1. France Osteoporosis Drugs Market Estimates and Forecast, 2022-2030 (US$ Bn)
9.3.2.2. France Osteoporosis Drugs, By Drug Class, 2022-2030 (US$ Bn)
9.3.2.3. France Osteoporosis Drugs, By Route of Administration, 2022-2030 (US$ Bn)
9.3.3. UK
9.3.3.1. UK Osteoporosis Drugs Market Estimates and Forecast, 2022-2030 (US$ Bn)
9.3.3.2. UK Osteoporosis Drugs, By Drug Class, 2022-2030 (US$ Bn)
9.3.3.3. UK Osteoporosis Drugs, By Route of Administration, 2022-2030 (US$ Bn)
9.3.4. Italy
9.3.4.1. Italy Osteoporosis Drugs Market Estimates and Forecast, 2022-2030 (US$ Bn)
9.3.4.2. Italy Osteoporosis Drugs, By Drug Class, 2022-2030 (US$ Bn)
9.3.4.3. Italy Osteoporosis Drugs, By Route of Administration, 2022-2030 (US$ Bn)
9.3.5. Spain
9.3.5.1. Spain Osteoporosis Drugs Market Estimates and Forecast, 2022-2030 (US$ Bn)
9.3.5.2. Spain Osteoporosis Drugs, By Drug Class, 2022-2030 (US$ Bn)
9.3.5.3. Spain Osteoporosis Drugs, By Route of Administration, 2022-2030 (US$ Bn)
9.3.6. Rest of Europe
9.3.6.1. Rest of Europe Osteoporosis Drugs Market Estimates and Forecast, 2022-2030 (US$ Bn)
9.3.6.2. Rest of Europe Osteoporosis Drugs, By Drug Class, 2022-2030 (US$ Bn)
9.3.6.3. Rest of Europe Osteoporosis Drugs, By Route of Administration, 2022-2030 (US$ Bn)

10. Asia Pacific Osteoporosis Drugs Market Analysis
10.1. Asia Pacific Osteoporosis Drugs Market, by Drug Class, 2022-2030(US$ Bn)
10.1.1. Overview
10.1.2. SRC Analysis
10.2. Asia Pacific Osteoporosis Drugs Market, by Route of Administration, 2022-2030(US$ Bn)
10.2.1. Overview
10.2.2. SRC Analysis
10.3. Asia Pacific Osteoporosis Drugs Market, by Country, 2022-2030 (US$ Bn)
10.3.1. China
10.3.1.1. China Osteoporosis Drugs, By Route of Administration, 2022-2030 (US$ Bn)
10.3.1.2. China Osteoporosis Drugs, By Drug Class, 2022-2030 (US$ Bn)
10.3.2. Japan
10.3.2.1. Japan Osteoporosis Drugs Market Estimates and Forecast, 2022-2030 (US$ Bn)
10.3.2.2. Japan Osteoporosis Drugs, By Drug Class, 2022-2030 (US$ Bn)
10.3.3. India
10.3.3.1. India Osteoporosis Drugs Market Estimates and Forecast, 2022-2030 (US$ Bn)
10.3.3.2. India Osteoporosis Drugs, By Drug Class, 2022-2030 (US$ Bn)
10.3.3.3. India Osteoporosis Drugs, By Route of Administration, 2022-2030 (US$ Bn)
10.3.4. South Korea
10.3.4.1. South Korea Osteoporosis Drugs Market Estimates and Forecast, 2022-2030 (US$ Bn)
10.3.4.2. South Korea Osteoporosis Drugs, By Drug Class, 2022-2030 (US$ Bn)
10.3.4.3. South Korea Osteoporosis Drugs, By Route of Administration, 2022-2030 (US$ Bn)
10.3.5. South-East Asia
10.3.5.1. South-East Asia Osteoporosis Drugs Market Estimates and Forecast, 2022-2030 (US$ Bn)
10.3.5.2. South-East Asia Osteoporosis Drugs, By Drug Class, 2022-2030 (US$ Bn)
10.3.5.3. South-East Asia Osteoporosis Drugs, By Route of Administration, 2022-2030 (US$ Bn)
10.3.6. Rest of Asia Pacific
10.3.6.1. Rest of Asia Pacific Osteoporosis Drugs Market Estimates and Forecast, 2022-2030 (US$ Bn)
10.3.6.2. Rest of Asia Pacific Osteoporosis Drugs, By Drug Class, 2022-2030 (US$ Bn)
10.3.6.3. Rest of Asia Pacific Osteoporosis Drugs, By Route of Administration, 2022-2030 (US$ Bn)

11. Latin America Osteoporosis Drugs Market Analysis
11.1. Latin America Osteoporosis Drugs Market, by Drug Class, 2022-2030(US$ Bn)
11.1.1. Overview
11.1.2. SRC Analysis
11.2. Latin America Osteoporosis Drugs Market, by Route of Administration, 2022-2030(US$ Bn)
11.2.1. Overview
11.2.2. SRC Analysis
11.3. Latin America Osteoporosis Drugs Market, by Country, 2022-2030 (US$ Bn)
11.3.1. Brazil
11.3.1.1. Brazil Osteoporosis Drugs Market Estimates and Forecast, 2022-2030 (US$ Bn)
11.3.1.2. Brazil Osteoporosis Drugs, By Drug Class, 2022-2030 (US$ Bn)
11.3.1.3. Brazil Osteoporosis Drugs, By Route of Administration, 2022-2030 (US$ Bn)
11.3.2. Mexico
11.3.2.1. Mexico Osteoporosis Drugs Market Estimates and Forecast, 2022-2030 (US$ Bn)
11.3.2.2. Mexico Osteoporosis Drugs, By Drug Class, 2022-2030 (US$ Bn)
11.3.2.3. Mexico Osteoporosis Drugs, By Route of Administration, 2022-2030 (US$ Bn)
11.3.3. Rest of Latin America
11.3.3.1. Rest of Latin America Osteoporosis Drugs Market Estimates and Forecast, 2022-2030 (US$ Bn)
11.3.3.2. Rest of Latin America Osteoporosis Drugs, By Drug Class, 2022-2030 (US$ Bn)
11.3.3.3. Rest of Latin America Osteoporosis Drugs, By Route of Administration, 2022-2030 (US$ Bn)

12. Middle East and Africa Osteoporosis Drugs Market Analysis
12.1. Middle East and Africa Osteoporosis Drugs Market, by Drug Class, 2022-2030(US$ Bn)
12.1.1. Overview
12.1.2. SRC Analysis
12.2. Middle East and Africa Osteoporosis Drugs Market, by Route of Administration, 2022-2030(US$ Bn)
12.2.1. Overview
12.2.2. SRC Analysis
12.3. Middle East and Africa Osteoporosis Drugs Market, by Country, 2022-2030 (US$ Bn)
12.3.1. GCC Countries
12.3.1.1. GCC Countries Osteoporosis Drugs Market Estimates and Forecast, 2022-2030 (US$ Bn)
12.3.1.2. GCC Countries Osteoporosis Drugs, By Drug Class, 2022-2030 (US$ Bn)
12.3.1.3. GCC Countries Osteoporosis Drugs, By Route of Administration, 2022-2030 (US$ Bn)
12.3.2. South Africa
12.3.2.1. South Africa Osteoporosis Drugs Market Estimates and Forecast, 2022-2030 (US$ Bn)
12.3.2.2. South Africa Osteoporosis Drugs, By Drug Class, 2022-2030 (US$ Bn)
12.3.2.3. South Africa Osteoporosis Drugs, By Route of Administration, 2022-2030 (US$ Bn)
12.3.3. Rest of Middle East and Africa
12.3.3.1. Rest of Middle East and Africa Osteoporosis Drugs Market Estimates and Forecast, 2022-2030 (US$ Bn)
12.3.3.2. Rest of Middle East and Africa Osteoporosis Drugs, By Drug Class, 2022-2030 (US$ Bn)
12.3.3.3. Rest of Middle East and Africa Osteoporosis Drugs, By Route of Administration, 2022-2030 (US$ Bn)

13. Company Profiles
13.1. Amgen Inc
13.1.1. Company Overview
13.1.2. Drug Classs/Inflammatory Bowel Disease Portfolio
13.1.3. Geographical Presence
13.1.4. Financial Summary
13.1.4.1. Market Revenue and Net Profit (2019-2022)
13.1.4.2. Business Segment Revenue Analysis
13.1.4.3. Geographical Revenue Analysis
13.2. Hoffmann-La Roche AG
13.3. Radius Health, Inc
13.4. Merck & Co. Inc.
13.5. Novartis International AG (Sandoz)
13.6. Pfizer Inc.
13.7. Sun Pharmaceutical Industries Ltd
13.8. Takeda Pharmaceutical Company Limited
13.9. Teva Pharmaceutical Industries Ltd

List of Figures
FIG. 1 Global Osteoporosis Drugs Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Osteoporosis Drugs Market Segmentation
FIG. 4 Global Osteoporosis Drugs Market, by Drug Class, 2022(US$ Bn)
FIG. 5 Global Osteoporosis Drugs Market, by Route of Administration, 2022 (US$ Bn)
FIG. 6 Global Osteoporosis Drugs Market, by Geography, 2022(US$ Bn)
FIG. 7 Attractive Investment Proposition, by Drug Class, 2022
FIG. 8 Attractive Investment Proposition, by Route of Administration, 2022
FIG. 9 Attractive Investment Proposition, by Geography, 2022
FIG. 10 Global Market Share Analysis of Key Osteoporosis Drugs Market Manufacturers, 2022
FIG. 11 Global Market Positioning of Key Osteoporosis Drugs Market Manufacturers, 2022
FIG. 12 Global Osteoporosis Drugs Market, by Drug Class, Value, 2022-2030(US$ Bn)
FIG. 13 Global Osteoporosis Drugs Market, by Route of Administration, Value, 2022-2030 (US$ Bn)
FIG. 14 Global Osteoporosis Drugs Market Value Contribution, By Drug Class, 2022&2030 (Value %)
FIG. 15 Global Osteoporosis Drugs Market, by Bisphosphonates, Value, 2022-2030(US$ Bn)
FIG. 16 Global Osteoporosis Drugs Market, by Selective Estrogen Inhibitors Modulator (SERM), Value, 2022-2030 (US$ Bn)
FIG. 17 Global Osteoporosis Drugs Market, by Parathyroid Hormone Therapy, Value, 2022-2030 (US$ Bn)
FIG. 18 Global Osteoporosis Drugs Market, by Calcitonin, Value, 2022-2030 (US$ Bn)
FIG. 19 Global Osteoporosis Drugs Market, by Rank Ligand Inhibitors, Value, 2022-2030 (US$ Bn)
FIG. 20 Global Osteoporosis Drugs Market, by Others, Value, 2022-2030 (US$ Bn)
FIG. 21 Global Osteoporosis Drugs Market Value Contribution, By Route of Administration, 2022&2030 (Value %)
FIG. 22 Global Osteoporosis Drugs Market, by Oral, Value, 2022-2030(US$ Bn)
FIG. 23 Global Osteoporosis Drugs Market, by Injectable, Value, 2022-2030 (US$ Bn)
FIG. 24 Global Osteoporosis Drugs Market, by Others, Value, 2022-2030 (US$ Bn)
FIG. 25 U.S. Osteoporosis Drugs Market, 2022-2030(US$ Bn)
FIG. 26 Canada Osteoporosis Drugs Market, 2022-2030(US$ Bn)
FIG. 27 Germany Osteoporosis Drugs Market, 2022-2030(US$ Bn)
FIG. 28 FranceOsteoporosis Drugs Market, 2022-2030(US$ Bn)
FIG. 29 U.K. Osteoporosis Drugs Market, 2022-2030(US$ Bn)
FIG. 30 ItalyOsteoporosis Drugs Market, 2022-2030(US$ Bn)
FIG. 31 Spain Osteoporosis Drugs Market, 2022-2030(US$ Bn)
FIG. 32 Rest of Europe Osteoporosis Drugs Market, 2022-2030(US$ Bn)
FIG. 33 China Osteoporosis Drugs Market, 2022-2030(US$ Bn)
FIG. 34 Japan Osteoporosis Drugs Market, 2022-2030(US$ Bn)
FIG. 35 IndiaOsteoporosis Drugs Market, 2022-2030(US$ Bn)
FIG. 36 South KoreaOsteoporosis Drugs Market, 2022-2030(US$ Bn)
FIG. 37 Southeast AsiaOsteoporosis Drugs Market, 2022-2030(US$ Bn)
FIG. 38 Rest of Asia Pacific Osteoporosis Drugs Market, 2022-2030(US$ Bn)
FIG. 39 Latin AmericaOsteoporosis Drugs Market, 2022-2030(US$ Bn)
FIG. 40 Brazil Osteoporosis Drugs Market, 2022-2030(US$ Bn)
FIG. 41 Mexico Osteoporosis Drugs Market, 2022-2030(US$ Bn)
FIG. 42 Rest of Latin AmericaOsteoporosis Drugs Market, 2022-2030(US$ Bn)
FIG. 43 Middle East & AfricaOsteoporosis Drugs Market, 2022-2030(US$ Bn)
FIG. 44 GCC CountriesOsteoporosis Drugs Market, 2022-2030(US$ Bn)
FIG. 45 South AfricaOsteoporosis Drugs Market, 2022-2030(US$ Bn)
FIG. 46 Rest of Middle East and AfricaOsteoporosis Drugs Market, 2022-2030(US$ Bn)

List of Tables
TABLE 1 Market Snapshot: Global Osteoporosis Drugs Market
TABLE 2 Global Osteoporosis Drugs Market, by Competitive Benchmarking,2022
TABLE 3 Global Osteoporosis Drugs Market, by Geographical Presence Analysis, 2022
TABLE 4 Global Osteoporosis Drugs Market, by Key Strategies Analysis, 2022
TABLE 5 Global Osteoporosis Drugs Market, by Drug Class, 2022-2030(US$ Bn)
TABLE 6 Global Osteoporosis Drugs Market, by Route of Administration, 2022-2030(US$ Bn)
TABLE 7 Global Osteoporosis Drugs Market, by Geography, 2022-2030(US$ Bn)
TABLE 8 North America Osteoporosis Drugs Market, by Drug Class, 2022-2030(US$ Bn)
TABLE 9 North America Osteoporosis Drugs Market, by Route of Administration, 2022-2030(US$ Bn)
TABLE 10 North America Osteoporosis Drugs Market, by Country, 2022-2030(US$ Bn)
TABLE 11 US Osteoporosis Drugs Market, by Drug Class, 2022-2030(US$ Bn)
TABLE 12 US Osteoporosis Drugs Market, by Route of Administration, 2022-2030(US$ Bn)
TABLE 13 Canada Osteoporosis Drugs Market, by Drug Class, 2022-2030(US$ Bn)
TABLE 14 Canada Osteoporosis Drugs Market, by Route of Administration, 2022-2030(US$ Bn)
TABLE 15 Europe Osteoporosis Drugs Market, by Drug Class, 2022-2030(US$ Bn)
TABLE 16 Europe Osteoporosis Drugs Market, by Route of Administration, 2022-2030(US$ Bn)
TABLE 17 Europe Osteoporosis Drugs Market, by Country, 2022-2030(US$ Bn)
TABLE 18 Germany Osteoporosis Drugs Market, by Drug Class, 2022-2030(US$ Bn)
TABLE 19 Germany Osteoporosis Drugs Market, by Route of Administration, 2022-2030(US$ Bn)
TABLE 20 France Osteoporosis Drugs Market, by Drug Class, 2022-2030(US$ Bn)
TABLE 21 France Osteoporosis Drugs Market, by Route of Administration, 2022-2030(US$ Bn)
TABLE 22 UK Osteoporosis Drugs Market, by Drug Class, 2022-2030(US$ Bn)
TABLE 23 UK Osteoporosis Drugs Market, by Route of Administration, 2022-2030(US$ Bn)
TABLE 24 Italy Osteoporosis Drugs Market, by Drug Class, 2022-2030(US$ Bn)
TABLE 25 Italy Osteoporosis Drugs Market, by Route of Administration, 2022-2030(US$ Bn)
TABLE 26 Spain Osteoporosis Drugs Market, by Drug Class, 2022-2030(US$ Bn)
TABLE 27 Spain Osteoporosis Drugs Market, by Route of Administration, 2022-2030(US$ Bn)
TABLE 28 Rest of Europe Osteoporosis Drugs Market, by Drug Class, 2022-2030(US$ Bn)
TABLE 29 Rest of Europe Osteoporosis Drugs Market, by Route of Administration, 2022-2030(US$ Bn)
TABLE 30 Asia Pacific Osteoporosis Drugs Market, by Drug Class, 2022-2030(US$ Bn)
TABLE 31 Asia Pacific Osteoporosis Drugs Market, by Route of Administration, 2022-2030(US$ Bn)
TABLE 32 Asia Pacific Osteoporosis Drugs Market, by Country, 2022-2030(US$ Bn)
TABLE 33 China Osteoporosis Drugs Market, by Drug Class, 2022-2030(US$ Bn)
TABLE 34 China Osteoporosis Drugs Market, by Route of Administration, 2022-2030(US$ Bn)
TABLE 35 Japan Osteoporosis Drugs Market, by Drug Class, 2022-2030(US$ Bn)
TABLE 36 Japan Osteoporosis Drugs Market, by Route of Administration, 2022-2030(US$ Bn)
TABLE 37 India Osteoporosis Drugs Market, by Drug Class, 2022-2030(US$ Bn)
TABLE 38 India Osteoporosis Drugs Market, by Route of Administration, 2022-2030(US$ Bn)
TABLE 39 South Korea Osteoporosis Drugs Market, by Drug Class, 2022-2030(US$ Bn)
TABLE 40 South Korea Osteoporosis Drugs Market, by Route of Administration, 2022-2030(US$ Bn)
TABLE 41 South East Asia Osteoporosis Drugs Market, by Drug Class, 2022-2030(US$ Bn)
TABLE 42 South East Asia Osteoporosis Drugs Market, by Route of Administration, 2022-2030(US$ Bn)
TABLE 43 Rest of Asia Pacific Osteoporosis Drugs Market, by Drug Class, 2022-2030(US$ Bn)
TABLE 44 Rest of Asia Pacific Osteoporosis Drugs Market, by Route of Administration, 2022-2030(US$ Bn)
TABLE 45 Latin America Osteoporosis Drugs Market, by Drug Class, 2022-2030(US$ Bn)
TABLE 46 Latin America Osteoporosis Drugs Market, by Route of Administration, 2022-2030(US$ Bn)
TABLE 47 Latin America Osteoporosis Drugs Market, by Country, 2022-2030(US$ Bn)
TABLE 48 Brazil Osteoporosis Drugs Market, by Drug Class, 2022-2030(US$ Bn)
TABLE 49 Brazil Osteoporosis Drugs Market, by Route of Administration, 2022-2030(US$ Bn)
TABLE 50 Mexico Osteoporosis Drugs Market, by Drug Class, 2022-2030(US$ Bn)
TABLE 51 Mexico Osteoporosis Drugs Market, by Route of Administration, 2022-2030(US$ Bn)
TABLE 52 Rest of Latin America Osteoporosis Drugs Market, by Drug Class, 2022-2030(US$ Bn)
TABLE 53 Rest of Latin America Osteoporosis Drugs Market, by Route of Administration, 2022-2030(US$ Bn)
TABLE 54 Middle East and Africa Osteoporosis Drugs Market, by Drug Class, 2022-2030(US$ Bn)
TABLE 55 Middle East and Africa Osteoporosis Drugs Market, by Route of Administration, 2022-2030(US$ Bn)
TABLE 56 Middle East and Africa Osteoporosis Drugs Market, by Country, 2022-2030(US$ Bn)
TABLE 57 GCC Countries Osteoporosis Drugs Market, by Drug Class, 2022-2030(US$ Bn)
TABLE 58 GCC Countries Osteoporosis Drugs Market, by Route of Administration, 2022-2030(US$ Bn)
TABLE 59 South Africa Osteoporosis Drugs Market, by Drug Class, 2022-2030(US$ Bn)
TABLE 60 South Africa Osteoporosis Drugs Market, by Route of Administration, 2022-2030(US$ Bn)
TABLE 61 Rest of Middle East and Africa Osteoporosis Drugs Market, by Drug Class, 2022-2030(US$ Bn)
TABLE 62 Rest of Middle East and Africa Osteoporosis Drugs Market, by Route of Administration, 2022-2030(US$ Bn)